Go Pro
NASDAQ:PLRZ

Polyrizon Q4 2025 Earnings Report

Polyrizon logo
$10.99 -0.04 (-0.36%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$10.66 -0.33 (-2.97%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Polyrizon EPS Results

Actual EPS
-$2.81
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Polyrizon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Polyrizon Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Polyrizon Earnings Headlines

Polyrizon (NASDAQ:PLRZ) Downgraded to "Sell" Rating by Wall Street Zen
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.tc pixel
See More Polyrizon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Polyrizon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Polyrizon and other key companies, straight to your email.

About Polyrizon

Polyrizon (NASDAQ:PLRZ) is an Israel-based biotechnology company developing hydrogel-based nasal products intended to provide localized protection in the nasal cavity. Its technology is designed to create a physical barrier that may help reduce exposure to airborne pathogens, allergens and other harmful particles before they enter the respiratory system.

The company’s platform focuses on nasal formulations and delivery systems that can adhere to the nasal mucosa and support applications in respiratory health. Potential product areas include protection against respiratory viruses, allergy-related symptoms and environmental pollutants, although the company’s products remain subject to development, testing and applicable regulatory requirements.

Polyrizon’s research and development activities are centered in Israel, with its products intended for potential use in international markets. The company’s technology is being developed for healthcare and consumer applications, but the availability, commercialization and regulatory status of specific products may vary by jurisdiction.

View Polyrizon Profile